TIGER Trial Results Presented for Rapid Medical’s Tigertriever to Treat Stroke

March 24, 2021—Rapid Medical announced that the company’s adjustable, fully visible Tigertriever stent retriever demonstrated superiority to existing self-expanding stent retrievers in the multicenter TIGER trial, with a statistically significant 11-point improvement in the ability to restore blood flow to the brain during ischemic stroke and equivalent safety.

The TIGER trial findings were presented at the American Stroke Association’s International Stroke Conference 2021, held virtually March 17-19, 2021. The study was also published by Rishi Gupta, MD, et al online in Stroke. Dr. Gupta and Jeffery L. Saver, MD, served as Principal Investigators.

“The trial confirmed that the Tigertriever is not only safe and effective but demonstrably improved outcomes over similar trials testing previous technology,” commented Dr. Saver in Rapid Medical’s press release. “Tigertriever is an important advance in stroke treatment devices and a win for patients.”

The company noted that the TIGER trial ended early after showing overwhelming effectiveness with 160 patients enrolled at 17 centers in the United States and Israel.

The trial demonstrated 84.6% revascularization success compared to a 73.4% average from six recent pivotal stent retriever trials. This improvement translates to significantly better patient outcomes, with 58% of patients living independently after 90 days versus an average of 43% of patients from the previous device trials. Additionally, the TIGER trial showed improved safety, with an 18.1% primary safety score versus a 20.4% historical average.

According to Rapid Medical, Tigertriever allows physicians to control the diameter and force in response to real-time anatomic and procedural information. This ability to respond to situational feedback is known as intelligent control. The TIGER trial concluded that these improvements provide meaningful benefit when removing the clot and treating stroke, stated the company.